Spravato® (esketamine) dosing follows strict FDA-approved guidelines to ensure safety, tolerability, and therapeutic effectiveness for individuals with treatment-resistant depression or major depressive disorder with suicidal ideation. The medication is administered intranasally in a certified clinical setting under medical supervision. Spravato® dosing is divided into two phases: an induction phase and a maintenance phase.
During induction, patients typically receive treatment twice per week for four weeks, with dosage determined by clinical assessment and response. After this initial period, the maintenance phase begins, with treatments generally reduced to once weekly for a month and then adjusted to every one to two weeks based on symptom stability and provider recommendation.
Patients can expect each Spravato® session to follow a structured protocol. Before dosing, clinicians review vital signs, mental status, and any side effects from previous sessions. The medication is self-administered under supervision, followed by a minimum two-hour monitoring period to assess blood pressure changes, dissociation, sedation, and overall response.
Because temporary cognitive and perceptual effects are common, patients must arrange transportation home and avoid driving until the next day. This carefully regulated dosing framework allows providers to optimize therapeutic benefit while maintaining a high standard of medical oversight and patient safety.
What Is the Recommended Spravato® Dosing Schedule for Depression?
The recommended Spravato® dosing schedule for depression follows a structured, FDA-approved protocol designed for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior. Treatment is divided into two primary phases: induction and maintenance, and it must be administered in a certified healthcare setting under medical supervision.
- Induction Phase (Weeks 1–4): Spravato® is typically administered twice per week for the first four weeks. The starting dose is generally 56 mg, with the possibility of increasing to 84 mg based on tolerability and clinical response. The goal during this phase is rapid symptom stabilization and measurable improvement in depressive severity.
- Maintenance Phase (Week 5 and beyond):
- Weeks 5–8: Usually administered once weekly.
- Week 9 and after: Typically reduced to every one to two weeks, depending on symptom stability and provider assessment.
Throughout Spravato® treatment for bipolar depression, patients are monitored for at least two hours after each dose due to potential side effects such as increased blood pressure, dissociation, or sedation. The dosing schedule may be adjusted based on clinical response, side effects, and overall treatment goals, but any changes must remain within FDA-approved guidelines.
How Is Spravato® Dosage Adjusted During Induction and Maintenance Phases?
Spravato® dosage adjustments during the induction and maintenance phases are guided by FDA-approved parameters, clinical response, and tolerability. The objective is to achieve meaningful symptom reduction after Spravato® treatment while minimizing adverse effects, all within a certified treatment setting under direct medical supervision.
- During the induction phase (Weeks 1–4): Treatment is administered twice weekly. The typical starting dose is 56 mg. Based on the patient’s response and side effect profile—such as dissociation, sedation, nausea, or transient blood pressure elevation—the dose may be increased to 84 mg as early as the second session. If side effects are clinically significant, providers may maintain the lower dose rather than escalate. The focus during induction is rapid stabilization, so dose optimization occurs early but cautiously.
- During the maintenance phase (Week 5 and beyond): From weeks 5–8, treatment is generally reduced to once weekly, and after Week 9, to every one to two weeks, depending on sustained improvement. The dose (56 mg or 84 mg) is individualized based on ongoing symptom control and tolerability. If depressive symptoms re-emerge, clinicians may increase treatment frequency within FDA guidelines rather than automatically increasing dosage. Conversely, if side effects outweigh the benefits, the dose may be reduced. Throughout both phases, patients are monitored for at least two hours post-administration. All dosing decisions are made in accordance with the Risk Evaluation and Mitigation Strategy (REMS) program requirements to ensure safety and regulatory compliance.
Mental Health Treatment That Works
Call 949-625-0564What our customers are saying
How Often Is Spravato® Taken and How Long Does Treatment Last?
Spravato® (esketamine) is taken according to a structured, FDA-approved schedule that includes an induction phase followed by a maintenance phase, with frequency decreasing over time as symptoms stabilize. During the first four weeks (induction), treatment is typically administered twice per week under medical supervision in a certified healthcare setting. This phase is designed to achieve rapid symptom reduction in individuals with treatment-resistant depression or major depressive disorder with suicidal ideation.
Beginning in Week 5, treatment usually shifts to once weekly for the next 4 weeks. After Week 9, dosing is commonly reduced to every one to two weeks, depending on clinical response and stability. The overall duration of treatment varies from individual to individual.
Some patients continue maintenance treatment for several months to sustain improvement, while others may taper under psychiatric guidance once symptoms are consistently managed. Because depression is often a chronic condition, treatment length is individualized and based on symptom remission, relapse risk, tolerability, and functional recovery.
What Factors Influence Spravato® Dosing and Safety Considerations?
Spravato® (esketamine) dosing is individualized within FDA-approved parameters and influenced by several clinical factors. Primary considerations include diagnosis and symptom severity, particularly whether the patient has treatment-resistant depression or major depressive disorder with acute suicidal ideation. Treatment history also plays a role, including prior antidepressant response, medication tolerance, and co-occurring psychiatric conditions.
Providers evaluate medical history, especially cardiovascular health, since Spravato® can cause transient increases in blood pressure. Age, concurrent medications (particularly CNS depressants), and history of substance misuse are also assessed to determine appropriate dosing (56 mg vs. 84 mg) and treatment frequency.
Safety considerations are central to every session and are governed by the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Spravato® must be administered in a certified clinical setting with pre- and post-dose monitoring, including blood pressure checks and observation for dissociation, sedation, perceptual changes, and cognitive impairment. Patients are monitored onsite for at least two hours and cannot drive until the following day.
Key Takeaways on Spravato® Dosing
- Spravato® follows a structured, FDA-approved dosing schedule consisting of an induction phase followed by a maintenance phase that gradually reduces frequency based on symptom stability.
- Dosage is individualized within approved limits (56 mg or 84 mg) and adjusted according to clinical response, tolerability, and side-effect profile, rather than a one-size-fits-all approach.
- Treatment frequency may be modified during maintenance if depressive symptoms re-emerge or if the patient achieves sustained improvement, ensuring flexibility within regulatory guidelines.
- Comprehensive safety monitoring is required under the REMS program, including blood pressure checks and at least two hours of post-dose observation to assess for dissociation, sedation, and other acute effects.
- Multiple clinical factors influence dosing decisions, including diagnosis, severity of depression, prior treatment history, cardiovascular health, concurrent medications, and overall functional progress.
The FDA has established specific dosing guidelines for Spravato® that emphasize the importance of safe, supervised treatment to ensure patients’ well-being. These protocols are designed to maximize treatment effectiveness while minimizing potential risks. If you’re interested in understanding how Moment of Clarity adheres to these approved Spravato® dosing standards or the cost of Spravato® without insurance, please don’t hesitate to reach out by calling 949-625-0564.
